請問POLYGYNAX是什麼藥

============================
圖片參考：http://hk.yimg.com/i/icon/16/8.gif

Polygynax in the treatment of fungal and non specific vaginitis.
Polygynax is a product commercialized in the form of vaginal capsule, associating bactericidal antibiotics: Neomycin, Polymyxin B and Nystatin--an antifungal agent which is fungicidal and fungistatic in vitro and in vivo. OBJECTIVE: The objectives of the study were to analyze the clinical and bacteriological efficacy of Polygynax in the treatment of bacterial vaginitis with one or more germs (mixed vaginitis) and Candida infections, and to investigate the correlation between the results of the initial clinical examination and bacteriological studies. MATERIAL AND METHODS: The study covered 88 patients diagnosed with mixed vaginitis during initial screening of vaginal flora (direct Gram stains and standard microbiology laboratory methods for cultivation of vagina/ cervix smears with antibiotic susceptibility testing). The patients were treated with Polygynax, applied in form of vaginal capsules (during 12 days, application before retiring). After at least 30 days following last day of therapy, the same diagnostic swabs were repeated. In this period, averaging 38.4 days, sexual abstinence was recommended. RESULTS: The results showed that total clearance of present germs was found in 83/88 patients (94.3% of the cases), according to the repeated cervico- vaginal smears. CONCLUSION: Polygynax is a treatment of preference against fungal infections, with added advantage of having wide antibacterial spectrum.

============================
圖片參考：http://hk.yimg.com/i/icon/16/8.gif

Use of Polygynax in pregnant women for preventing cervico-vaginal infections
115 women, distributed in 20 centres, were included in a randomized study designed to assess the efficacy of Polygynax in preventing vaginal infections in women at risk, at the start of pregnancy. Polygynax proved to be markedly effective since only 9.6% of the patients in the Polygynax group had a vaginal infection, in contrast to 42.6% of the patients in the control group. This result is highly significant (p less than 0.0001) and confirms the advantage attached to the use of Polygynax when a first line treatment involving the use of several drugs in combination is indicated.
============================
圖片參考：http://hk.yimg.com/i/icon/16/8.gif